FDA approved a supplemental Biologics License Application expanding the MACI (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size. MACI Arthro provides a less invasive technique compared to the current approach, allowing surgeons to evaluate and prepare the defect site as well as deliver the MACI implant through small incisions using custom-designed MACI Arthro instruments.
MACI is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. MACI is the only restorative biologic cartilage repair product approved for arthroscopic administration.
MACI Arthro incorporates advantages of an arthroscopic approach with the long-term durability and established clinical results of MACI. Custom MACI Arthro instruments are designed to treat the most common defects in the MACI addressable market, which are 2-4cm2 defects on the femoral condyles.
Nick Colangelo, President and CEO of Vericel, said, “MACI Arthro provides orthopedic surgeons and their patients with a less invasive option for MACI administration, which we believe has the potential to significantly increase penetration into the largest segment of the MACI addressable market and will support sustained top-tier revenue growth for the company in the years ahead.”
FDA approved a supplemental Biologics License Application expanding the MACI (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size. MACI Arthro provides a less invasive technique...
FDA approved a supplemental Biologics License Application expanding the MACI (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size. MACI Arthro provides a less invasive technique compared to the current approach, allowing surgeons to evaluate and prepare the defect site as well as deliver the MACI implant through small incisions using custom-designed MACI Arthro instruments.
MACI is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. MACI is the only restorative biologic cartilage repair product approved for arthroscopic administration.
MACI Arthro incorporates advantages of an arthroscopic approach with the long-term durability and established clinical results of MACI. Custom MACI Arthro instruments are designed to treat the most common defects in the MACI addressable market, which are 2-4cm2 defects on the femoral condyles.
Nick Colangelo, President and CEO of Vericel, said, “MACI Arthro provides orthopedic surgeons and their patients with a less invasive option for MACI administration, which we believe has the potential to significantly increase penetration into the largest segment of the MACI addressable market and will support sustained top-tier revenue growth for the company in the years ahead.”
Copy to clipboard 
